195 related articles for article (PubMed ID: 30838908)
21. Vancomycin Combined With Clindamycin for the Treatment of Acute Bacterial Skin and Skin-Structure Infections.
Wargo KA; McCreary EK; English TM
Clin Infect Dis; 2015 Oct; 61(7):1148-54. PubMed ID: 26082508
[TBL] [Abstract][Full Text] [Related]
22. Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis.
Baltin CT; Wulf C; Rongisch R; Lehmann C; Wingen-Heimann S; Eisenmenger N; Bonn J; Fabri M; von Stebut E; Cornely OA; Kron F
J Infect Public Health; 2023 Jun; 16(6):955-963. PubMed ID: 37099955
[TBL] [Abstract][Full Text] [Related]
23. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
[TBL] [Abstract][Full Text] [Related]
24. Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.
Saddler K; Zhang J; Sul J; Patel P; Castro-Lainez M; Stevens ML; Kosler S; Lowery E; Sierra-Hoffman M
PLoS One; 2021; 16(3):e0248129. PubMed ID: 33735185
[TBL] [Abstract][Full Text] [Related]
25. Dalbavancin Use in the Emergency Department Setting.
Patel M; Smalley S; Dubrovskaya Y; Siegfried J; Caspers C; Pham V; Press RA; Papadopoulos J
Ann Pharmacother; 2019 Nov; 53(11):1093-1101. PubMed ID: 31155916
[No Abstract] [Full Text] [Related]
26. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
[TBL] [Abstract][Full Text] [Related]
27. Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).
Amara S; Adamson RT; Lew I; Huang X
Curr Med Res Opin; 2013 Jul; 29(7):869-77. PubMed ID: 23659559
[TBL] [Abstract][Full Text] [Related]
28. Outcomes associated with initial versus later vancomycin use in patients with complicated skin and skin-structure infections.
Itani KM; Akhras KS; Stellhorn R; Quintana A; Budd D; Merchant S
Pharmacoeconomics; 2009; 27(5):421-30. PubMed ID: 19586079
[TBL] [Abstract][Full Text] [Related]
29. Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections.
LaPensee K; Mistry R; Lodise T
Am Health Drug Benefits; 2019 Feb; 12(1-Supplement 2):S13-S24. PubMed ID: 30996767
[TBL] [Abstract][Full Text] [Related]
30. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.
Li JZ; Willke RJ; Rittenhouse BE; Rybak MJ
Surg Infect (Larchmt); 2003; 4(1):57-70. PubMed ID: 12744768
[TBL] [Abstract][Full Text] [Related]
31. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
[TBL] [Abstract][Full Text] [Related]
32. Single-dose oritavancin in the treatment of acute bacterial skin infections.
Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
[TBL] [Abstract][Full Text] [Related]
34. The Impact of FASTPASS: A Collaboration With Emergency Department to Improve Management of Patients With Gallbladder Disease and Acute Appendicitis.
Kulvatunyou N; Zimmerman SA; Adhikhari S; Joseph B; Gries L; Tang AL; Rhee P
J Surg Res; 2021 Apr; 260():293-299. PubMed ID: 33360754
[TBL] [Abstract][Full Text] [Related]
35. Emergency department care of ABSSSI with dalbavancin infusion, direct discharge, and outpatient telemedicine follow up: a study protocol.
Durante-Mangoni E; Riccardi A; Guarino M; Cesaro F; Lugarà M; Mascolo S; Morelli L; Natale V; Andreoni M
J Chemother; 2023 Sep; 35(5):397-403. PubMed ID: 36264157
[TBL] [Abstract][Full Text] [Related]
36. Association of emergency department and hospital characteristics with elopements and length of stay.
Handel DA; Fu R; Vu E; Augustine JJ; Hsia RY; Shufflebarger CM; Sun B
J Emerg Med; 2014 Jun; 46(6):839-46. PubMed ID: 24462026
[TBL] [Abstract][Full Text] [Related]
37. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
McCollum M; Sorensen SV; Liu LZ
Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
[TBL] [Abstract][Full Text] [Related]
38. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections.
Rappo U; Gonzalez PL; Puttagunta S; Akinapelli K; Keyloun K; Gillard P; Liu Y; Dunne MW
J Glob Antimicrob Resist; 2019 Jun; 17():60-65. PubMed ID: 30797084
[TBL] [Abstract][Full Text] [Related]
39. Impact of a bronchiolitis guideline on ED resource use and cost: a segmented time-series analysis.
Akenroye AT; Baskin MN; Samnaliev M; Stack AM
Pediatrics; 2014 Jan; 133(1):e227-34. PubMed ID: 24324000
[TBL] [Abstract][Full Text] [Related]
40. Optimizing skin and skin structure infection outcomes: considerations of cost of care.
Almarzoky Abuhussain SS; Goodlet KJ; Nailor MD; Nicolau DP
Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):235-244. PubMed ID: 29521147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
